HLA-E and ovarian carcinoma: This is in line with reports on breast and ovarian cancer, where HLA-G or HLA-E expression correlated with a worse overall and event-free survival [15] and also in rectal and colon cancers, in which a combination of the immune-related markers HLA class I, HLA-G, HLA-E and FoxP3 reflect an immune escape mechanism [29, 30].